Post-essential Thrombocythemia Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-essential Thrombocythemia Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis [Phase 3]
Phase 3 trial of ruxolitinib in primary myelofibrosis and related post-PV/post-ET myelofibrosis has completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]
Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminate…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) [Phase 4]
Completed Phase 4 exploratory study of INC424 (nilotinib) in patients with primary myelofibrosis or post-polycythemia vera myelofibrosis or …
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial investigates an alternative dosing strategy for ruxolitinib in myelofibrosis, with completed results posted in 2014.